FILTER
FILTERED INTERVIEW RESULTS
Barbara Weber
CEO, TANGO THERAPEUTICS
Tango Therapeutics is targeting unaddressed disease mechanisms in cancer to develop transformational new drugs for patients.
Michael Bigham & Evan Loh
PARATEK PHARMACEUTICALS
Paratek focuses on drugs that target infectious disease and other difficult-to-treat conditions.
Richard Peters
PRESIDENT AND CEO, MERRIMACK PHARMACEUTICALS
Merrimack Pharmaceuticals is focused on cancer treatment through a deeper understanding of cancer pathways and biological markers.
Ankit Mahadevia & Cristina Larkin
CEO & CHIEF COMMERCIAL OFFICER, SPERO THERAPEUTICS
Spero Therapeutics is developing new antimicrobial drugs to substitute those that have become ineffectual as they meeting resistance.
Travis McCready
PRESIDENT & CEO, MASSACHUSETTS LIFE SCIENCES CENTER
The Massachusetts Life Sciences Center has spent a billion dollars to ensure the best possible environment for the life sciences industry.
Robert K. Coughlin
PRESIDENT & CEO, MASSACHUSETTS BIOTECHNOLOGY COUNCIL
Founded in 1985, MassBio’s mission is to advance Massachusetts’ leadership in life sciences to grow the industry.
Thomas Wicks
CHIEF STRATEGY OFFICER, TRIALSCOPE
TrialScope helps trial sponsors to comply with disclosure regulations and internal transparency policies for jurisdictions across the world and is developing a program to provide easily intelligible interpretations of trial results for the patients that are involved in trials.
Valarie Higgins
PRESIDENT & MANAGING DIRECTOR, ALMAC CLINICAL TECHNOLOGIES
Almac Clinical Technologies designs and deploys complex software that helps trial sponsors automate complex decisions that occur in clinical trials.
Josh Grauso
SALES MANAGER, UL CONSUMER & RETAIL SERVICES
UL helps companies meet safety and compliance standards and regulations across the pharma industry.
Christian Kopfli
CEO, CHROMOCELL
Chromocell is using its own Chrmovert technology to provide alternative pain blockers to opioids.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
